

HCS HB 1962 -- LIMITS ON SELLING OR PURCHASING CERTAIN DRUGS

SPONSOR: Peters

COMMITTEE ACTION: Voted "Do Pass with HCS" by the Standing Committee on Health and Mental Health by a vote of 16 to 0.

The following is a summary of the House Committee Substitute for HB 1962.

Current law prohibits the sale, purchase, or dispensation of ephedrine, phenylpropanolamine, or pseudoephedrine to the same individual in a 12-month period in an amount greater than 43.2 grams. This bill changes that yearly limit to 61.2 grams.

The bill requires, beginning on October 1, 2026, any manufacturer of compounds, mixtures, or preparations specified in the bill to pay monthly fees to the administrator of the real-time electronic pseudoephedrine tracking system. The fee levels are to be set by the administrator. No manufacturer will be assessed fees based upon transactions attributable to the compounds, mixtures, or preparations of any other manufacturer.

This bill provides that a manufacturer commits the offense of unlawful sale, distribution, or purchase of over-the-counter methamphetamine precursor drugs if the manufacturer knowingly fails to pay the fees required by the provisions of this bill.

This bill is similar to HB 1036 (2025).

The following is a summary of the public testimony from the committee hearing. The testimony was based on the introduced version of the bill.

PROPONENTS: Supporters say that currently, Missouri is the most restrictive state when it comes to purchasing limits, and that people with severe allergies deserve relief and the ability to buy more of the medication they rely on.

Testifying in person for the bill were Representative Peters; Haleon c/o Multistate Associates LLC; Arnie Dienoff; Consumer Healthcare Products Association.

OPPONENTS: There was no opposition voiced to the committee.

Written testimony has been submitted for this bill. The full written testimony and witnesses testifying online can be found under Testimony on the bill page on the House website.